Selected Slide Presentations
Click on the links below to view presentations.

Plenary Speakers

Cellular cofactors of HIV integrase as novel antiviral targets
Zeger Debyser; K.U. Leuven, Belgium

Resistance to New Antiretroviral Agents

Potent HIV-1 Entry Inhibitors with a Reserve of Binding Energy Against Resistance Mutations
Michael Kay; University of Utah School of Medicine, USA           

Resistance to CCR5mAb RoAb3952 is Associated with a Shift in Binding from the Extracellular Domain 2 to the N-Terminus of CCR5
Andreas Jekle; Roche Palo Alto, USA

Novel Resistance Profile of the Potent Nucleoside Analog Reverse Transcriptase Inhibitor
3?-Azido-2?,3?-Dideoxyguanosine (AZG)
Jeffrey Meteer; University of Pittsburgh, USA

Hexadecyloxypropyl tenofovir (CMX157) Has Enhanced Potency in Vitro against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile
Randall Lanier; Chimerix Inc., USA

In vitro Cross-Resistance Profile, Antiviral Activity, Safety and Pharmacokinetics in HIV-1-Infected Subjects of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance
Robert Murphy; Northwestern University Feinberg School of Medicine, USA

Longitudinal Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir:  Results from P005 a Phase 2 Study in Treatment Experienced Patients
Michael Miller; Merck & Co., Inc., USA

HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457)
Scott McCallister; Panacos Pharmaceuticals, USA

Mechanisms of HIV Drug Resistance

Structural Explanations to Altered Drug Resistance Pathways in HIV-1 Non-Clade B Proteases
Rajintha Bandaranayake; University of Massachusetts Medical School, USA

How HCV NS3-4A Protease R155K/T Strains Can Discriminate VX-950 but affect differentially SCH-503034
Jerome Courcambeck; GenoScience, France

Structural Basis for K65R Function: Tenofovir Resistance, Reduced Nucleotide Incorporation and Excision Antagonism
Kalyan Das; CABM & Rutgers University, USA

AZT Resistance Related Connection Mutations in HIV-1 RT Cause Selective Dissociation from RNase H-Competent Complexes
Maryam Ehteshami; McGill University, Canada

Q509L in HIV-1 RT Increases AZT Resistance by Promoting Polymerase-Competent vs. RNase H-Competent Binding on RNA/DNA T/P with Short Duplex Lengths
Jessica Brehm; University of Pittsburgh, USA

Delayed Chain-Termination Protects the HBV Drug Entecavir from Excision by HIV-1 Reverse Transcriptase
Matthias Götte; McGill University, Canada

HIV Pathogenesis, Fitness and Resistance

Single Cell Analysis of HIV DNA from Infected Patients
Sarah Palmer; Karolinska Institute, Sweden

Correlations between Transmitted HIV-1 Drug Resistance Mutations and the HLA Alleles of Therapy-Naïve HIV-Patients
Rolf Kaiser; University of Cologne, Germany

HIV-1 Recombination in Patients Infected with Multiple HIV-1 Variants from the Same Donor
Mary Kearney; National Cancer Institute, USA

Intensification with Efavirenz or Lopinavir/Ritonavir Does Not Reduce Residual HIV-1 Viremia in Patients on Standard Antiretroviral Therapy
Frank Maldarelli; HIV Drug Resistance Program, USA

New Resistance Technologies and Interpretations

Improved Genotypic Prediction Of HIV-1 Coreceptor Usage By Incorporating V2 Loop Sequence Variation
Alexander Thielen; Max-Planck Institute for Informatics, Germany

Inferring viral tropism from genotype with massively parallel sequencing: Qualitative and quantitative analysis
Martin Daumer; Institute of Immunology and Genetics, Germany

Clinical Implications of Resistance

Emergence of drug resistance after failure of first line HAART is associated with intensity of virological monitoring: A systematic analysis of cohort and trial data specifically addressing the WHO public health approach to antiretroviral therapy
Ravindra Gupta; Royal Free and University College Medical School ,University College London, UK

Low frequency K103N mutations are strongly associated with inadequate virologic responses to NNRTI-based therapy
Gillian Hunt; National Institute for Communicable Diseases, South Africa

Determination of Phenotypic Clinical Cut-offs for Etravirine: Pooled Week 24 Results of the DUET-1 and DUET-2 trials
Monika Peeters; Tibotec BVBA, Beligum